Abstract
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials. The article does not provide specific management recommendations but highlights important practical aspects of antiplatelet therapy, including optimal dosing, the variable balance between benefits and risks when antiplatelet therapies are used alone or in combination with other antiplatelet drugs in different clinical settings, and the implications of persistently high platelet reactivity despite such treatment.
MeSH terms
-
Aspirin / adverse effects
-
Aspirin / pharmacokinetics
-
Aspirin / therapeutic use
-
Cilostazol
-
Dipyridamole / adverse effects
-
Dipyridamole / pharmacokinetics
-
Dipyridamole / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Evidence-Based Medicine*
-
Humans
-
Platelet Activation / drug effects
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Practice Guidelines as Topic*
-
Randomized Controlled Trials as Topic
-
Societies, Medical*
-
Tetrazoles / adverse effects
-
Tetrazoles / pharmacokinetics
-
Tetrazoles / therapeutic use
-
Thienopyridines / adverse effects
-
Thienopyridines / pharmacokinetics
-
Thienopyridines / therapeutic use
-
Thrombosis / blood
-
Thrombosis / drug therapy*
-
Thrombosis / prevention & control*
-
United States
Substances
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Tetrazoles
-
Thienopyridines
-
Dipyridamole
-
Cilostazol
-
Aspirin